Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:VANI

Vivani Medical Q2 2025 Earnings Report

Vivani Medical logo
$1.25 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 +0.01 (+1.20%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Vivani Medical EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Announcement Details

Quarter
Q2 2025
Date
8/13/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Vivani Medical's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Vivani Medical's Q2 2025 Press ReleasePress Release
(8-K)
Vivani Medical's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Vivani Medical Earnings Headlines

Williams Gregg buys Vivani medical (VANI) shares worth $1.99m
April 16, 2026  |  investing.comhttps://www.investing.com/news/insider-trading-news/williams-gregg-buys-vivani-medical-vani-shares-worth-199m-93CH-4617531
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
April 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vivani-medical-price-target-lowered-155153203.html
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
May 6 at 1:00 AM  |  Reagan Gold Group (Ad)
Vivani Medical (VANI) price target increased by 10.00% to 5.61
March 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/vivani-medical-vani-price-target-increased-by-1000-to-561/ar-AA1Zxqiw
Vivani Medical, Inc. Advances NPM-139 Semaglutide Implant toward Phase 1 Clinical Study Following Successful LIBERATE-1 Trial and Positive Preclinical Data
March 26, 2026  |  quiverquant.comQ
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/26/3263430/0/en/vivani-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update.html
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) Solutions, Inc. (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity. These products aim to reduce complications associated with percutaneous biopsies while facilitating efficient sample collection and handling, helping clinicians deliver faster and more accurate diagnoses.

Vivani Medical serves a broad customer base that encompasses hospitals, outpatient imaging centers and pathology service providers across the United States. In addition to its direct‐sales model, the company has established distribution partnerships to extend its reach into select European and Latin American markets, supporting growing international adoption of its technologies.

Founded in 2016 and headquartered in the United States, Vivani Medical became a publicly traded company in mid-2021, listing its common stock on the Nasdaq Capital Market under the ticker symbol “VANI.” The company’s leadership team brings together experienced professionals in medical device innovation, regulatory affairs and commercial operations, driving ongoing efforts to expand its product pipeline and reinforce its position in the interventional radiology market.

View Vivani Medical Profile
Earnings Tools